Recent data and studies have highlighted the effectiveness of the newly approved RSV preventive shot, Beyfortus, in reducing hospitalization rates among infants. Developed by AstraZeneca and Sanofi, Beyfortus has been shown to be 90% effective at preventing RSV-associated hospitalizations in children, with a median time from receipt to symptom onset of 45 days and a 95% confidence interval (CI) of 75%–96%, according to a CDC study. This comes as a significant development in the fight against the Respiratory Syncytial Virus (RSV), a major cause of respiratory illness in young children. While the vaccine's success is being celebrated, there have also been concerns raised about the potential increase in risk of a rare neurological condition associated with RSV vaccines.
RSV shot for infants 90 percent effective against hospitalizations https://t.co/IYDm0HoxYh
RSV shot for infants 90 percent effective against hospitalizations: CDC | The RSV preventive shot for infants approved last year was 90 percent effective at preventing hospitalizations. READ MORE: https://t.co/9dvhBaR6Uk
Astra-Sanofi's RSV therapy 90% effective against infant hospitalizations, CDC study shows https://t.co/ZgxcGAq7f9 https://t.co/lySoD6YgBK
How effective were new RSV shots for babies? Early @CDCgov estimates found nirsevimab (aka Beyfortus by @sanofi/@AstraZeneca) was "90% (95% CI = 75%–96%) against RSV-associated hospitalization with a median time from receipt to symptom onset of 45 days" https://t.co/Q4n9hUoc3g https://t.co/o8LQZKlJZn https://t.co/Q1fecUSvPO
Beyfortus, a new shot for RSV, was 90% effective at preventing hospitalizations in children, new data shows. https://t.co/vDzlIwX466
US data suggest nirsevimab, the #RSV monoclonal sold as Beyfortus, was really effective in protecting against RSV hospitalizations for the babies lucky enough to get a dose. https://t.co/wH8CbR2FMd
RSV Vaccines May Increase Risk Of Rare Neurological Condition https://t.co/rVLmAkDC7x